Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics study of [14C] TAS-303 in healthy adult males
jRCT2071220056Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-303, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Blood and plasma radioactivity and TAS-303 pharmacokinetics, Urinary and fecal radioactivity excretion and 2 more. Started Sep 2022; status: completed.
02
Drugs
TAS-303
Beyond the preview
Go deeper on jRCT2071220056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220056.